Decoding Aging through iPSC Reprogramming: Advances and Challenges

利用诱导多能干细胞重编程解码衰老:进展与挑战

阅读:4

Abstract

Aging is characterized by cellular senescence and increased susceptibility to age-related diseases. Induced pluripotent stem cell (iPSC) technology demonstrates the potential to reverse aging hallmarks, including telomere attrition, mitochondrial dysfunction, and oxidative stress. Reprogramming somatic cells using factors such as Oct4, Sox2, Klf4, and c-Myc (OSKM) restores pluripotency and reverses aging markers. Partial reprogramming, involving transient OSKM expression, rejuvenates cells by resetting epigenetic clocks, reducing senescence-associated secretory phenotypes (SASPs), and improving mitochondrial function, as evidenced by lifespan extension in progeroid mouse models. These advancements facilitate disease modeling and autologous therapies for neurodegeneration, etc. Critical challenges, including tumorigenicity risks associated with oncogenic reprogramming factors, have been mitigated through non-integrative delivery systems (e.g., mRNA, small molecules) and suicide genes. Persistent epigenetic memory and incomplete reprogramming impede iPSC differentiation, but CRISPR-based tools (e.g., dCas9-DNMT3A, CRISPRoff) allow precise epigenetic editing to erase residual somatic signatures. Variability in iPSC quality, influenced by cell source and culture conditions, necessitates standardized protocols and CRISPR-enhanced quality control. Ethical considerations, such as informed consent and genetic discrimination, highlight the need for governance frameworks that align innovation with societal values. Subsequent priorities include optimizing reprogramming efficiency, validating safety in preclinical models, and translating findings into therapies for age-related disorders. In conclusion, iPSC and CRISPR technologies collectively present transformative strategies to delay aging and restore cellular vitality, paving the way for rejuvenation therapies. Future studies should focus on improving the reprogramming efficiency, minimizing the risk of tumorigenicity, and exploring the optimized CRISPR-based epigenetic editing technique.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。